Market Access Call Competence -training program

Pharma market is rapidly changing, and a new broad base of stakeholders is impacting the uptake and use of pharmaceutical products. In Europe, breakthrough innovations can obtain marketing approval via Prime Fast Track program. New innovations tend to have a high price tag and at launch from the payer’s perspective, there is often significant uncertainty of the clinical outcomes in real life.

Cost-effectiveness has supplemented the established notions of safety, efficacy and quality as a further requirement to secure market access. Common consensus is that the traditional pharma sales model is no longer sufficient since engaging with payers and other budget holders require a different approach compared to the traditional industry methodology. Market Access Call Competence training program is designed in collaboration with pharma companies and is carried out by Medaffcon’s senior specialists.

Upon completing the program you will be able to:

  • Understand the implications your product has on the wider healthcare market and the operating units within it.
  • Understand the impact that the changing decision-making processes in healthcare will have on your product.
  • Prepare a positive and constructive approach so that the healthcare environment supports the uptake of your product.
  • Communicate the value of your product to the different stakeholders who influence uptake.

 

The objective of the program is to enhance the necessary skills and capabilities of Field Based Execution of Market Access Strategy of key customer-facing people in pharma companies and to execute a company-specific strategically important Market Access project.

 

The program covers the following topics:

  • Pharma environment in Finland; Policy and stakeholders
  • Price and reimbursement application processes
  • Hospital tendering processes
  • Key elements of Health Economics
  • Real World Evidence; Sources and use in practice
  • Patient access Schemes and Risk Sharing Agreements in hospitals and retail market
  • The use of Health Economics and RWE in negotiations
”This training provides a very broad and comprehensive understanding of the changing business environment in the pharma and health care industries in Finland. Sales skills with product and therapy area knowledge are no longer sufficient; one must also understand the operative principles of health care from the perspectives of the payer and the society”
Participant
”The small group training works well, enables an interactive atmosphere, and facilitates a lot of discussions. Medaffcon’s trainers are the top subject matter experts in Finland with extensive experience and knowledge on the course subjects. Pre-class materials are available in advance and company-specific projects are mentored by Medaffcon.”
Participant
”An extremely good course; I recommend it to everyone working with Key Opinion Leaders and/or decision makers at the health care district level.”
Participant at the MACC-training program

We are more than happy to tell you more!!

Elisa Tyynysniemi
Scientific Project Manager

Contact us

Our Market Access Call Competence Experts:

Elisa Tyynysniemi
Scientific Project Manager

Elisa Tyynysniemi

Scientific Project Manager
M.Sc. (Pharmaceutical Science)

+358 40 839 4369 LinkedIn

Elisa joined Medaffcon’s team in January 2015. Before that, Elisa studied Biomedicine at the University of Turku and completed a master’s degree in a program for international drug development at the University of Copenhagen. She has worked as a researcher at the Department of Pathology of the University of Turku, marketing authorization coordinator at the Finnish Medicines Agency, Fimea, and in pharmacovigilance positions in Copenhagen. At Medaffcon, Elisa has worked as a scientific expert in various client companies and, among other things, written scientific reviews and therapeutic values.

Elisa brings an extensive background in medicine, pharmacy, and economics to Medaffcon. In the pharmaceutical industry, she is interested in the seamless co-operation between different mission profiles and working towards common goals. Elisa is particularly interested in the digitalization of science and knowledge management. “It is exciting to see how different clients utilize digital platforms in order to share information and to improve patient safety”.


Jarmo Hahl
Managing Director

Jarmo Hahl

Managing Director
M.Sc. (Economics)

+358 40 139 4001 LinkedIn

Jarmo joined Medaffcon as a partner and CEO in 2010, having previously worked in various expert and management positions in pharma companies for eight years. Jarmo has a degree in economics and before entering the pharmaceutical industry, he held an office at the Turku School of Economics and also worked as a research fellow at Turku University Hospital.

Jarmo has strong expertise in new health technology innovations and how the demands and expectations of authorities, markets and customers are matched. He also brings to Medaffcon extensive experience in health economics and its applications in research and commercialization, as well as a broad understanding of the ever-changing operating environment. “From an access point of view, the Finnish health technology market is constantly becoming more demanding and therefore also more attractive from my point of view. On the other hand, increasing demands to demonstrate the effectiveness and cost-effectiveness of healthcare are broadening the scope and opportunities for Medaffcon to be involved in the development of healthcare as a whole”.


Kalle Snicker
Sr. Market Access Manager

Kalle Snicker

Sr. Market Access Manager
M.Sc.

+358 40 052 6597 LinkedIn

Kalle Snicker joined Medaffcon’s team in September 2017. He has a long history in the pharmaceutical industry. Over the years, he has gained experience in leading positions in sales and marketing, running the Baltic business unit, and in recent years, leading the oncology market access functions at Novartis Finland.

At Medaffcon, Kalle has been developing the introduction of hospital medicines, together with various pharmaceutical companies and authorities. In recent years, there has been a significant development in the introduction of hospital medicines, with the focus on the evaluation of medicines. The development and implementation of such evaluation are one of Kalle’s strongest competencies, which can benefit any actor in the industry.

Kalle’s strengths include his extensive and comprehensive view on how the industry functions as well as his ability to predict how future challenges can be considered and how the best possible result for the patient can be achieved in a new operational environment.